Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer.
about
Taxanes in the Treatment of Advanced Gastric CancerCan S-1 replace fluorouracil for advanced gastric cancer? A PRISMA-compliant systematic review and meta-analysisNon-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan.Efficacy and safety of taxane-based systemic chemotherapy of advanced gastric cancer: A systematic review and meta-analysis.Platinum-based versus non-platinum-based chemotherapy as first line treatment of inoperable, advanced gastric adenocarcinoma: a meta-analysis.S-1-based chemotherapy versus capecitabine-based chemotherapy as first-line treatment for advanced gastric carcinoma: a meta-analysis.Cisplatin or not in advanced gastric cancer: a systematic review and meta-analysis.The efficacy and toxicity of paclitaxel plus S-1 compared with paclitaxel plus 5-FU for advanced gastric cancer: a PRISMA systematic review and meta-analysis of randomized controlled trials.A case report of curative distal gastrectomy for stage IV gastric cancer after chemoradiotherapy in a patient with a gastrojejunal gastric bypass.A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.Chemotherapy for advanced gastric cancer.High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients.The Efficacy and Safety of First-line Chemotherapy in Advanced Esophagogastric Cancer: A Network Meta-analysis.Short-term efficacy of different chemotherapy regimens in the treatment of advanced gastric cancer: a network meta-analysis.Prognostic Role of Conversion Surgery for Unresectable Gastric Cancer.
P2860
Q26747708-060212F3-431A-4036-A7AC-F386ED2CF054Q33433129-FDCCAC00-5F28-4D84-A0EE-30523B6338C1Q33594906-8E3CF995-EA67-45C1-92FF-E7DC20E5ACCDQ33902814-06193022-3A8E-4346-A11B-7BCDF94B0A18Q34852173-A229C0F6-4DCD-438D-9161-87C0AB79A02CQ35070531-602FABA0-19B7-45B0-A36B-A46D69641912Q35080136-57A4C6C8-D857-47D1-B588-D5C0B2A607AAQ36193781-2749807C-E6F3-45E3-AEF1-787216D5C426Q37410030-AE45FF83-6DDE-4C6D-99B3-701684F8F81EQ37702562-6660C291-2A7C-4943-89F4-90EC0E3D33C8Q38604012-E15F4D14-16AC-4EEA-89E5-2F8CAB722741Q38882319-5E97AEAD-1BBB-4073-A15C-1E15094E980FQ38941416-8BADF8B1-1D02-4701-8B81-A645998EDD1EQ41044387-EE7B44AE-2C3F-4C0E-B42E-BF797D950663Q53622300-9C671601-116A-4F51-9104-DE98AE955F20
P2860
Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Phase II multi-institutional p ...... rrent advanced gastric cancer.
@ast
Phase II multi-institutional p ...... rrent advanced gastric cancer.
@en
type
label
Phase II multi-institutional p ...... rrent advanced gastric cancer.
@ast
Phase II multi-institutional p ...... rrent advanced gastric cancer.
@en
prefLabel
Phase II multi-institutional p ...... rrent advanced gastric cancer.
@ast
Phase II multi-institutional p ...... rrent advanced gastric cancer.
@en
P2093
P2860
P356
P1476
Phase II multi-institutional p ...... rrent advanced gastric cancer.
@en
P2093
North Kanto Gastric Cancer Study Group
P2860
P2888
P356
10.1038/BJC.2012.222
P407
P577
2012-05-22T00:00:00Z